Evidence map›Paper›PMID 42016148›Full record

ArticleClinical & translational immunology2026

cGAS inhibitor IMSB301 modifies interferon signalling in peripheral mononuclear cells of

Velda X Han, Jessica P Hayes, Lijun Sun, Teresa Mooneyham, Michelle Lorentzos, Hiroya Nishida, Markus J Hofer, Brian Gloss, Ruwani Dissanayake, Xianzhong Lau and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical & translational immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Therapeutic targeting of the cGAS-STING pathway in human disease.The Journal of clinical investigation · 2026
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Velda X HanKhoo Teck Puat-National University Children's Medical Institute, National University Health System Singapore Singapore.
Jessica P HayesKids Neuroscience Centre, The Children's Hospital at Westmead, Faculty of Medicine and Health, University of Sydney Sydney NSW Australia.
Lijun SunImmuneSensor Therapeutics Dallas TX USA.
Teresa MooneyhamImmuneSensor Therapeutics Dallas TX USA.
Michelle LorentzosKids Advanced Therapeutics, Kids Research, Sydney Children's Hospitals Network Sydney NSW Australia.ORCID https://orcid.org/0009-0005-9608-6535
Hiroya NishidaKids Neuroscience Centre, The Children's Hospital at Westmead, Faculty of Medicine and Health, University of Sydney Sydney NSW Australia.
Markus J HoferSchool of Life and Environmental Sciences and Charles Perkins Centre, Faculty of Science University of Sydney Sydney NSW Australia.ORCID https://orcid.org/0000-0001-5111-3978
Brian GlossWestmead Research Hub, Westmead Institute for Medical Research Westmead NSW Australia.
Ruwani DissanayakeAustralian Genome Research Facility Ltd Westmead NSW Australia.
Xianzhong LauAustralian Genome Research Facility Ltd Melbourne VIC Australia.
Shekeeb S MohammadKids Neuroscience Centre, The Children's Hospital at Westmead, Faculty of Medicine and Health, University of Sydney Sydney NSW Australia.ORCID https://orcid.org/0000-0003-1219-4781
Shrujna PatelKids Neuroscience Centre, The Children's Hospital at Westmead, Faculty of Medicine and Health, University of Sydney Sydney NSW Australia.
Russell C DaleKids Neuroscience Centre, The Children's Hospital at Westmead, Faculty of Medicine and Health, University of Sydney Sydney NSW Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Aicardi-Goutières syndrome (AGS) is a rare genetic interferonopathy because of aberrant DNA or RNA metabolism that lacks effective disease modifying therapies. Methods: Single-cell RNA sequencing was performed on peripheral blood mononuclear cells (PBMCs) obtained from a patient with AGS because of pathogenic biallelic Results: In PBMCs from the patient with Conclusion: The cGAS inhibitor IMSB301 resulted in specific reduction in interferon signalling

Indexed as

Aicardi–Goutières syndromecGAS‐STING pathwayneuroinflammationtherapeutics

Identifiers

PMID42016148
PMCPMC13093634

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.